M46
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with inflammatory rheumatic diseases (e.g., rheumatoid arthritis, spondyloarthritis (psoriatic arthritis, axial spondyloarthritis), myositis, scleroderma, vasculitis), patients at increased risk of developing inflammatory rheumatic diseases (psoriasis, anti-CCP-positive patients (preRA)), and patients with degenerative joint diseases (gonarthrosis) are being recruited for the study. - Age > 18 years - Written consent to participate in the study and data protection - Willingness and ability to participate in the study; sufficient knowledge of German to understand the consent form and questionnaires, or, if this is not possible, information for participants and support in their native language or, if necessary, in English. - High probability that patients will be able to participate in the full scope of the study. - A signed consent form is required for all patients to participate in this study (the information and consent form is included with the application).
Exclusion criteria
Exclusion criteria: - Pregnancy - No change in systemic immunosuppressive therapy in the last 3 months and during the intervention period (follow-up is excluded).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Can the quality of life (SF-36) of rheumatic patients be improved within 8 weeks using the PhysioFit app? 2. Can pain (PAIN, VRS) be reduced in patients with rheumatic diseases within 8 weeks using the PhysioFit app? | — |
Secondary
| Measure | Time frame |
|---|---|
| Does the use of the PhysioFit app lead to an improvement in health and exercise competence (PAHCO, EQ-5D-L) in patients with rheumatic diseases within 8 weeks? 2. How does the PhysioFit app influence exercise anxiety (TSK) in patients with rheumatic diseases within 8 weeks? | — |
Countries
Germany
Contacts
Uniklinik Erlangen